Literature DB >> 10026131

An intramembrane modulator of the ErbB2 receptor tyrosine kinase that potentiates neuregulin signaling.

K L Carraway1, E A Rossi, M Komatsu, S A Price-Schiavi, D Huang, P M Guy, M E Carvajal, N Fregien, C A Carraway, K L Carraway1.   

Abstract

The ErbB2 receptor tyrosine kinase plays a critical role in a variety of developmental processes, and its aberrant activation may contribute to the progression of some breast and ovarian tumors. ASGP2, a transmembrane glycoprotein found on the surface of the highly metastatic ascites 13762 rat mammary adenocarcinoma cell line, is constitutively associated with ErbB2 in these cells and in mammary tissue from pregnant rats. Expression studies indicate that ASGP2 interacts directly and specifically with ErbB2 through one of its epidermal growth factor-like domains and that the co-expression of the two proteins in the same cell dramatically facilitates their direct stable interaction. Ectopic expression of ASGP2 in human melanoma tumor cells potentiates the response of endogenous ErbB2 to the neuregulin-1 growth factor. These observations point to a novel intramembrane mechanism for the modulation of receptor tyrosine kinase activity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10026131     DOI: 10.1074/jbc.274.9.5263

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

Review 1.  Mucins and blastocyst attachment.

Authors:  Amantha Thathiah; Daniel D Carson
Journal:  Rev Endocr Metab Disord       Date:  2002-05       Impact factor: 6.514

2.  Mechanistic and signaling analysis of Muc4-ErbB2 signaling module: new insights into the mechanism of ligand-independent ErbB2 activity.

Authors:  Goldi A Kozloski; Coralie A Carothers Carraway; Kermit L Carraway
Journal:  J Cell Physiol       Date:  2010-09       Impact factor: 6.384

3.  Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies.

Authors:  Albert C Chen; Ilenia Migliaccio; Mothaffar Rimawi; Sara Lopez-Tarruella; Chad J Creighton; Suleiman Massarweh; Catherine Huang; Yen-Chao Wang; Surinder K Batra; M Carolina Gutierrez; C Kent Osborne; Rachel Schiff
Journal:  Breast Cancer Res Treat       Date:  2012-05-29       Impact factor: 4.872

Review 4.  The ErbB receptors as targets for breast cancer therapy.

Authors:  J Albanell; J Baselga
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

5.  Muc4-ErbB2 complex formation and signaling in polarized CACO-2 epithelial cells indicate that Muc4 acts as an unorthodox ligand for ErbB2.

Authors:  Victoria P Ramsauer; Vanessa Pino; Amjad Farooq; Coralie A Carothers Carraway; Pedro J I Salas; Kermit L Carraway
Journal:  Mol Biol Cell       Date:  2006-04-19       Impact factor: 4.138

Review 6.  Muc4/MUC4 functions and regulation in cancer.

Authors:  Kermit L Carraway; George Theodoropoulos; Goldi A Kozloski; Coralie A Carothers Carraway
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

Review 7.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

8.  The membrane mucin Muc4 inhibits apoptosis induced by multiple insults via ErbB2-dependent and ErbB2-independent mechanisms.

Authors:  Heather C Workman; Colleen Sweeney; Kermit L Carraway
Journal:  Cancer Res       Date:  2009-03-17       Impact factor: 12.701

9.  MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells.

Authors:  Pallavi Chaturvedi; Ajay P Singh; Subhankar Chakraborty; Subhash C Chauhan; Sangeeta Bafna; Jane L Meza; Pankaj K Singh; Michael A Hollingsworth; Parmender P Mehta; Surinder K Batra
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

10.  Regulation of the membrane mucin Muc4 in corneal epithelial cells by proteosomal degradation and TGF-beta.

Authors:  Joseph Lomako; Wieslawa M Lomako; Coralie A Carothers Carraway; Kermit L Carraway
Journal:  J Cell Physiol       Date:  2010-04       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.